Publication Beamlines Strategic Pillar
(2019). Prolactin receptor binding proteins and uses thereof. Patent Number: IL239502B.
(2021). Methods for improving response to anti-lif antibody treatment in individuals with cancer. Patent Number: IL279484A.
(2020). Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer. Patent Number: IL277918A.
(2021). Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer. Patent Number: IL279444A.
(2021). ANTIBODY. Patent Number: PT3311170T.
(2022). Surgical method for treatment of auditory disease or condition. Patent Number: GB202213060D0.
(2022). Nanoparticle platform for antibody and vaccine delivery. Patent Number: PT3661968T.
(2021). MODELING TEST. Patent Number: PT3311169T.
(2021). Stable heterodimeric antibody design with mutations in the fc domain. Patent Number: PT2773671T.
(2022). ANTIBODY EPITOPE. Patent Number: PT3311171T.
(2020). ANTI-BCMA ANTIBODIES, BIESPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND THEIR USES. Patent Number: PT3337824T.
호안 세오안 수아레즈; 후디트 아니도 폴구에이라; 요한 프란손; 로빈 매튜 할렛; 모니카 파스쿠알 가르시아 et al. (2021). Combination of LIF inhibitor and PD-1 axis inhibitor for use in treating cancer. Patent Number: KR20210021287A.
호안 세오안 수아레즈; 후디트 아니도 폴구에이라; 로빈 매튜 홀레트; 파트리샤 앤 깁린; 잔느 마그람 et al. (2021). Combination of LIF inhibitors and platinum-based anti-neoplastic agents for use in treating cancer. Patent Number: KR20210022065A.
호안 세오안 수아레즈; 후디트 아니도 폴구에이라; 로빈 매튜 홀레트; 피터 에드워드 베일리스; 아지타 제가나탄 et al. (2021). Methods for improving response to anti-LIF antibody treatment in a subject with cancer. Patent Number: KR20210024007A.
본 크로덴슈타인 토마스 스프리터; 서짓 비마라오 딕시트; 카브레라 에릭 에스코바; 폴라 아이린 라리오; 데이빗 카이 위엔 푼 et al. (2019). Stable heterodimeric antibody design with mutations in the fc domain. Patent Number: KR102052774B1.